Inside Medicare's new GLP-1 demonstration

On July 1, 2026, the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge Program — a temporary demonstration giving eligible Medicare beneficiaries access to certain weight-loss medications for a flat $50 monthly copay. 

It is, on its face, a meaningful expansion of access to drugs that have changed the standard of care for obesity and related conditions. It is also more complicated, more limited, and more temporary than most of the early news coverage suggested. For plan sponsors, TPAs, and the retirees and members they serve, understanding the actual mechanics of this program, and its pitfalls, matters.

How the bridge program actually works

The first thing to understand is what this program is not. The Medicare GLP-1 Bridge is a Section 402 demonstration run by CMS — it does not constitute a Medicare Part D plan offering prescription drug coverage. That distinction is not a technicality. It shapes everything else about how the program functions.

The Bridge Program runs from July 1, 2026, through December 31, 2027, and operates entirely outside the standard Part D benefit. Rather than going through a beneficiary's existing Part D plan, a central system run by Medicare handles approvals, processes claims, and pays pharmacies directly.

Read more: Expanding HSA eligibility could pay for GLP-1s  

What's covered

Three GLP-1 products are eligible under the Bridge: Foundayo, Wegovy (both injection and tablet formulations), and Zepbound — though only the KwikPen formulation of Zepbound qualifies. The single-dose vial and single-dose pen formulations of Zepbound are explicitly excluded. 

Who qualifies

To be eligible, a beneficiary must be 18 or older and meet one of three clinical thresholds: a BMI of 35 or higher; a BMI of 30 or higher with a qualifying condition such as heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher with risk factors like pre-diabetes, a prior heart attack, or peripheral artery disease.

On the plan side, beneficiaries must be enrolled in a standalone Part D plan or a Medicare Advantage coordinated care plan that includes drug coverage. Employer and union group waiver plans, Special Needs Plans, and dually eligible beneficiaries who meet the clinical criteria are all eligible to participate. Private fee-for-service plans, cost contract plans, health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans are not eligible. If your organization sponsors retiree coverage through any of these excluded plan types, your members are not getting access to this program.

What it costs and how to access benefits

Eligible beneficiaries pay a fixed $50 monthly copayment. Because the drugs are furnished outside the standard Part D benefit, none of that copay counts toward a beneficiary's true out-of-pocket costs, and low-income cost-sharing subsidies do not apply to any portion of it. Manufacturers will provide the eligible drugs at a net price of $245 per monthly supply, and that price does not count toward a beneficiary's gross covered prescription drug costs either.

A medical provider must submit a prior authorization request along with a prescription for an eligible GLP-1 drug to a central processor — not to CMS directly. 

Read more: GLP-1s and menopause benefits are here to stay — What it means for 2026 budgets

The bridge was supposed to lead somewhere

The Bridge Program was never designed to be permanent. It was originally set to run alongside a planned successor — the Better Approaches to Lifestyle and Nutrition for Comprehensive Health  (BALANCE) Model — which would have allowed Part D plans to opt in to ongoing GLP-1 coverage for weight loss starting in January 2027. Unfortunately, the BALANCE model was delayed indefinitely while the GLP-1 Bridge itself was extended through December 31, 2027. 

The population most CMS programs protect is excluded here

Most Medicare demonstration programs build in protections for low-income subsidy-eligible beneficiaries precisely because affordability is often an access barrier. Although $50 sounds affordable, it is a barrier for many who would have benefited most from this protection.  

What this means for plan sponsors and administrators

This program sits at an unusual intersection: real and meaningful for the members who qualify, structurally uncertain beyond its 2027 sunset, and operationally complex enough that misinformation will spread faster than accurate guidance unless plan sponsors get ahead of it.  

For employers and group plan sponsors with retiree populations

• Confirm plan type eligibility now. If your retiree drug coverage runs through an EGWP, your population is eligible — but you should be coordinating with your PBM and TPA to understand how Bridge claims will appear (or not appear) in your data, since they run entirely outside the standard Part D claims flow.

• Get ahead of the BMI-at-initiation rule. Members and their physicians need to understand that historical BMI at the start of therapy — not current BMI — determines eligibility. This will generate confusion and appeals without proactive communication.

• Don't let members assume this is permanent. Any member communication about this program should be explicit that it is a temporary demonstration set to end December 31, 2027, with no confirmed permanent successor in place.
  

Most importantly, make sure you're working with a partner that is reading the fine print on your behalf and guiding you through all the potential pitfalls. This is very complex legislation, and any misunderstandings could be costly for you and your employees/retirees.